Company profile

ACS Biomarker BV is a Dutch biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers that improve prognosis and management of cardiac disease. 

Product development

ACS Biomarker concentrates on developing novel biomarkers for the diagnosis and prognosis of patients with heart failure. The company discovered Galectin-3, the first protein-based prognostic biomarker for heart failure that is now in the clinic. The past years ACS Biomarker’s research focus was on miRNAs. miRNAs represent a new class of circulating biomarkers that are remarkably stable and can be easily detected in blood samples. ACS Biomarker was the first company to identify a series of microRNAs that can be used for the diagnosis and prognosis of heart failure.

In current practice clinical symptoms and multiple measurements of diagnostic biomarkers (BNP, NTproBNP) and of prognostic markers such as Galectin-3 are required to optimally assess the clinical condition of a heart failure patient.

The key objective of ACS Biomarker is to develop one multi-marker test that simultaneously provides diagnostic and prognostic information and can distinguish between the different heart failure subtypes. A quick and simplified diagnostic procedure that leads to a better understanding of the cardiovascular status will result in better treatment decisions and improved patient outcomes.

Heart Failure

Heart failure is one of the most common causes of death. Ageing of the population and novel treatment strategies prolonging the lives of cardiac patients led to an increase in the incidence of heart failure. Despite improved treatments the mortality rate in patients with heart failure is very high. Early diagnosis is critically important, as early treatment of the disease gives the best possible results.

News & events

ACS Biomarker announced today that it has strengthened the organization to manage its participation in several European biomarker research collaborations and to accelerate the biomarker validation activities in its new state-of-the-art lab facility. ACS Biomarker BV is a Dutch biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers that improve prognosis and management of cardiac disease.